BioCentury
ARTICLE | Company News

Qiagen, Eli Lilly deal

June 9, 2014 7:00 AM UTC

Qiagen partnered with Eli Lilly to co-develop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types. The deal focuses on undisclosed biomarkers targeting cellular pathways associated with undisclosed Lilly oncology compounds. The deal includes tests that will be based on Qiagen's multi-modal, multi-analyte Modaplex analysis platform, which can process multiple sample types and biomarkers in a single test. Qiagen declined to disclose financial terms and directed questions to Lilly, which could not be reached for details.

The deal is the fourth between Qiagen and Lilly. Last November, the companies partnered to develop a PCR-based molecular companion diagnostic for an undisclosed Lilly oncology compound. Last February, the partners signed a master agreement to develop and commercialize companion diagnostics for the pharma's investigational and approved products across all therapeutic areas (see BioCentury, Feb. 18, 2013 & Nov. 25, 2013). ...